All In Biotech

Free tool

FAERS Monitor: Clarinex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021363 or its brand name (Clarinex, Desloratadine). Reports on generic versions are filed under their own applications.

Reports

10,834

Serious

8,441

78% of reports

Hospitalization

4,109

Death reported

608

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective630
  • fatigue629
  • nausea607
  • dyspnoea544
  • headache485
  • diarrhoea471
  • dizziness458
  • pruritus445
  • vomiting417
  • rash396
  • off label use357
  • pyrexia333
  • pain332
  • asthenia327
  • arthralgia321

Reports by year received

View as table
YearReports
2004467
2005347
2006311
2007355
2008292
2009283
2010341
2011444
2012459
2013255
2014246
2015425
2016480
2017401
2018628
2019738
2020653
2021516
2022683
2023601
2024764
2025603
2026542

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pruritusSignal4452.22.1313
pyrexia3331.91.7136
dyspnoea5441.91.7224
dizziness4581.81.6160
rash3961.81.6133
vomiting4171.71.6128
asthenia3271.71.593
fatigue6291.61.5134
headache4851.51.483
arthralgia3211.51.354
nausea6071.51.4101
diarrhoea4711.41.359
pain3321.00.91
drug ineffective6300.90.94
off label use3570.80.720

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.